Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementAetna Weight Reduction Coverage & Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0039

    Weight Reduction Programs and Devices

    Customize your policy alerts

    Sign up for Aetna Policy 0039 alerts

    Get alerted when Policy 0039 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, exclusions, and coding for clinician-supervised weight reduction programs, very low calorie diets, weight reduction devices (including Plenity), and weight reduction medications; applies to Aetna members and their providers.

    Policy Summary
    PayerAetna
    PolicyWeight Reduction Programs and Devices
    Policy CodePolicy 0039
    Change TypeNo material change
    Effective DateFeb 14, 2000
    Last ReviewMar 15, 2023
    Next Review DateJan 11, 2024
    Key ActionDocument baseline BMI, weight-related comorbidities, and 16-week weight change to support initiation and continuation of liraglutide or device coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    26Clinician counseling visits limit
    16wVLCD monitoring period
    BMI 25-40Plenity indication
    >=30Adult obesity BMI threshold
    01/11/2024Next review

    Coverage Criteria

    Clinician Supervised Weight Reduction Programs

    Covered when ALL of the following are met:

    Adult counseling visit limit: Up to a combined limit of 26 individual or group visits by any recognized provider per 12-month period is medically necessary for weight reduction counseling in adults who are obese (BMI >=30 kg/m2)26 visits/12 months

    Number of visits for obese children left to physician discretion

    Medical Evaluation and VLCD Monitoring

    Covered when ALL of the following evaluation/monitoring elements are performed as clinically indicated:

    Baseline evaluation tests: Complete blood count; comprehensive history and physical examination; lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides); metabolic and chemistry profile (serum chemistries, liver tests, uric acid); thyroid function tests (T3, T4, TSH); urinalysis; electrocardiogram (adult); glucose tolerance test when indicated; dexamethasone suppression testing and 24-hour urinary free cortisol if Cushing's suspected; hand x-ray for bone age in children.
    Policy Summary
    PayerAetna
    PolicyWeight Reduction Programs and Devices
    Policy CodePolicy 0039
    Change TypeNo material change
    Effective DateFeb 14, 2000
    Last ReviewMar 15, 2023
    Next Review DateJan 11, 2024
    Key ActionDocument baseline BMI, weight-related comorbidities, and 16-week weight change to support initiation and continuation of liraglutide or device coverage.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and RequirementsBackground and Evidence SummariesDefinitions

    Tests ordered/performed as clinically indicated

    VLCD monitoring: For very low calorie diets (VLCD; <799 kcal/day): EKG after 50 pounds of weight loss; lipid profile at beginning and end of the VLCD program; serum chemistries and liver function tests weekly during the rapid weight loss phase then every 2 weeks thereafter up to 16 weeks.VLCD monitoring up to 16 weeks

    VLCDs beyond 16 weeks are subject to medical review

    Plenity (Gelesis) Coverage

    Covered when ALL of the following are met:

    Plenity indication: FDA-cleared Plenity (Gelesis) is medically necessary to aid weight management in overweight and obese adults when used in conjunction with diet and exercise and the member's BMI is between 25 and 40 kg/m2.BMI 25-40 kg/m2

    Device is FDA-cleared; no specific HCPCS code

    Experimental / Investigational (Not Covered)

    The following are considered experimental and investigational because effectiveness has not been established:

    Experimental procedures list: Acupuncture for weight loss; body plethysmography (diagnostic study); boron compound administration; low-level laser therapy; dual-energy X-ray (DEXA) whole-body composition; fat mass and obesity-associated (FTO) genotyping; gastric electrical stimulation; human chorionic gonadotropin (HCG) or vitamin injections for weight loss; indirect calorimetry (oxygen uptake analysis); normobaric hypoxic conditioning; sodium-glucose co-transporter 2 (SGLT2) inhibitors for weight reduction; wearable devices (e.g., Fitbit or health apps on mobile phones); whole-body calorimetry and whole-body bioimpedance analysis for weight reduction and related indications.

    Specific items enumerated in policy

    Hospital Confinement

    Hospital confinement for a weight reduction program is considered not medically necessary.

    Pharmacotherapy (liraglutide) criteria

    Evidence-supported uses and required monitoring

    Liraglutide initiation and continuation: Patient selection: adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one weight-related comorbidity; therapy is adjunctive to a reduced-calorie diet and increased physical activity; evaluate weight loss at 16 weeks and discontinue if patient has not lost at least 4% of baseline body weight.16-week ≥4% weight loss

    Includes boxed warning regarding rodent thyroid C-cell tumors and contraindication in personal/family history of medullary thyroid carcinoma (MTC) or MEN2; do not combine with other GLP-1 receptor agonists.

    Very-low-energy diets

    Very-low-energy diets (VLED)

    VLED supervised use: Very-low-energy diets can be used safely in supervised conditions for up to 3 months (≤3 months) in patients who have not achieved target weight loss with standard reduced-energy approaches; longer-term benefits are uncertain and studies are heterogeneous.<=3 months supervised

    Longer-term outcomes require further standardized evidence

    DEXA, BIA/BIVA, and indirect calorimetry stance

    Body composition and metabolic measurement tools

    Measurement modalities not established to improve outcomes: Whole-body DEXA, whole-body bioimpedance/BIA/BIVA, and indirect calorimetry have limited or mixed evidence that their routine use improves clinical outcomes in obesity management compared with simpler measures (BMI and anthropometrics); these modalities are primarily for research or selected clinical contexts where utility is documented.clinical utility not established

    Some modalities show reliability or validity concerns and require further validation in specific populations

    Under most benefit plans, services and supplies for weight reduction are specifically excluded from coverage. Examples include exercise programs or use of exercise equipment, prepackaged diet supplements/foods (for example, Optifast liquid protein meals, NutriSystem, Medifast foods, or similar products), and commercial weight-loss programs such as Weight Watchers, Jenny Craig, Diet Center, or Zone diet. Refer to the member’s benefit plan for specific exclusions that may affect payment or authorization.

    Whole-body dual-energy X-ray absorptiometry (DEXA) and whole-body bioelectrical impedance analysis (BIA)/bioelectrical impedance vector analysis (BIVA) are not supported as routine clinical tools to manage obesity. Available evidence does not demonstrate that whole-body DEXA or whole-body bioimpedance measurements improve clinical management or outcomes compared with simpler approaches such as BMI and anthropometric measures, and current guidelines do not endorse substituting these modalities for standard assessments.

    Plenity (an oral superabsorbent hydrogel) has contraindications and precautions that must be observed. It is contraindicated in pregnancy and in individuals with a history of allergic reaction to components such as cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide. Use should be avoided or carefully considered in patients with esophageal anatomic anomalies, suspected strictures, or prior gastrointestinal surgery or other conditions that could affect swallowing or gastrointestinal transit; patients should be instructed to contact their healthcare provider for severe adverse events or if they have difficulty swallowing capsules.

    The background sections of this policy summarize evidence reviews and literature for a range of interventions (for example, wearable devices, boron compounds, and SGLT2 inhibitors) and provide references. These background summaries are intended to inform clinicians and reviewers and do not by themselves state explicit coverage, exclusion, or medical necessity determinations for the interventions described; coverage decisions are defined in the policy’s coverage criteria and exclusions sections.

    This Clinical Policy Bulletin contains a partial, general description of plan or program benefits and is provided to assist in administering benefits. It does not constitute a contract or guarantee of coverage. Specific plan provisions, member eligibility, and benefit limitations determine actual coverage; treating providers remain responsible for clinical care decisions.

    Hospital confinement for the purpose of a weight reduction program is considered not medically necessary and therefore is not covered.

    Dietary supplements marketed for weight loss such as glucomannan and pyruvate lack convincing evidence of clinically meaningful weight reduction and have limited safety data; randomized trials show at best small effects of uncertain clinical importance and report adverse events (for example, gastrointestinal symptoms and potential lipid changes). These products are not supported as medically necessary treatments for obesity.

    Coding

    Covered CPT Codes (if selection criteria met)CPTCovered
    97802Medical nutrition therapy; initial assessment and intervention, individual, each 15 minutes
    97803Re-assessment and intervention, individual, each 15 minutes
    97804Group (2 or more individuals), each 30 minutes
    mixed
    No codes listed
    CPT Codes not covered (for indications listed)CPTNot Covered
    0358TBioelectrical impedance analysis whole body composition assessment, with interpretation and report
    94690Oxygen uptake, expired gas analysis; Rest, indirect (indirect calorimetry)
    94726Plethysmography for determination of lung volumes (body plethysmography)
    97810Acupuncture, one or more needles without electrical stimulation; initial 15 minutes
    97811Acupuncture, without electrical stimulation, each additional 15 minutes
    97813Acupuncture, with electrical stimulation; initial 15 minutes
    97814Acupuncture, with electrical stimulation, each additional 15 minutes
    Other CPT Codes related to the CPBCPT
    77072Bone age studies
    80048Basic metabolic panel
    80053Comprehensive metabolic panel
    80418Combined rapid anterior pituitary evaluation panel
    80420Dexamethasone suppression panel, 48 hour
    81000Urinalysis, non-automated
    82465Cholesterol, serum or whole blood, total
    82951Glucose tolerance test (GTT), three specimens
    83718HDL cholesterol
    84443Thyroid stimulating hormone (TSH)
    1–10 of 12
    1/2
    Covered HCPCS Codes (if selection criteria met)HCPCSCovered
    G0270Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year, individual, each 15 minutes
    G0271Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year, group, each 30 minutes
    HCPCS not covered/related codesHCPCSNot Covered
    J0725Injection, chorionic gonadotropin, per 1,000 USP units
    J7336Capsaicin 8% patch, per sq cm
    S8948Application of a modality; low-level laser; each 15 minutes
    S9449Weight management classes, non-physician provider, per session
    S9451Exercise classes, non-physician provider, per session
    S9452Nutrition classes, non-physician provider, per session
    ICD-10 Codes (covered if selection criteria met)ICD-10Covered
    E66.01-E66.9Overweight and obesity
    Z68.25-Z68.45BMI codes 25.0–40+ (adult)
    Device / HCPCS (Plenity)HCPCSCovered
    HCPCS: PlenityPlenity (Gelesis, Inc.) - no specific HCPCS code
    VLCD duration monitoring
    VLCD monitoring periodMedically necessary monitoring (EKG after 50 lb loss; lipid profile start and end; weekly serum chemistries and LFTs during rapid weight loss then every 2 weeks) is covered for up to 16 weeks after VLCD initiation
    VLCD definitionVery Low Calorie Diet (VLCD) defined as <799 kcal/day
    Extension beyond 16 weeksVLCDs extending beyond 16 weeks are subject to medical review to determine if additional services are medically necessary
    Clinician counseling visits
    Combined visit limitUp to a combined limit of 26 individual or group clinician-supervised weight reduction visits per 12-month period for adults who are obese (BMI ≥30 kg/m2)
    Provider typesVisits may be provided by any recognized provider (individual or group formats)
    Pediatric noteNumber of medically necessary visits for obese children left to the discretion of the member's physician
    Liraglutide 16-week response threshold
    16-week response thresholdDiscontinue liraglutide if patient has not lost at least 4% of baseline body weight at 16 weeks, per FDA labeling
    RationaleEvaluation at 16 weeks predicts likelihood of sustained clinically meaningful weight loss with continued treatment
    DocumentationDocument baseline weight and percent change at ~16 weeks to justify continuation or discontinuation
    BMI indications for chronic weight management medications
    Primary BMI indicationBMI ≥30 kg/m2 for initiation of chronic weight management medications (e.g., liraglutide)
    Overweight with comorbidityBMI ≥27 kg/m2 with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
    Adjunct requirementMedications should be adjunct to reduced-calorie diet and increased physical activity

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization and covered codes

    Clinician-supervised weight reduction counseling codes (97802, 97803, 97804) and medical nutrition HCPCS (G0270, G0271) are covered when selection criteria are met; Plenity is covered when criteria are met though no specific HCPCS code exists.

    • Covered CPT: 97802, 97803, 97804 (medical nutrition therapy) when selection criteria are met.
    • Covered HCPCS: G0270, G0271 when selection criteria are met.
    • Plenity (Gelesis) is considered medically necessary for BMI 25–40 kg/m2 when used with diet and exercise; no specific HCPCS code is listed.
    Prior Authorization

    Prior authorization expectations for liraglutide

    Initiation and continuation of liraglutide (Saxenda) must be justified by BMI criteria (BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one weight‑related comorbidity) and therapy should be evaluated at 16 weeks to document response.

    • Document baseline BMI/weight and comorbidities to support initiation (BMI ≥30 or ≥27 with comorbidity).
    • Evaluate weight loss at 16 weeks and discontinue if the patient has not lost ≥4% of baseline body weight per FDA labeling.
    Note

    Plenity: labeling, indication, and dosing

    Plenity is FDA‑cleared as an adjunct to diet and exercise for adults with BMI 25–40 kg/m2; device labeling specifies dosing of three capsules (2.25 g/dose) with water before lunch and dinner and recommends use within a structured weight loss program.

    • Each dose: three (3) capsules = 2.25 g, taken with water before lunch and dinner.
    • Indication: adults with BMI 25–40 kg/m2, used in conjunction with diet and exercise.
    • Payer documentation may require evidence of selection criteria and concurrent lifestyle measures evaluated in trials.
    Prior Authorization

    Prior authorization — none specified

    The background/appendix supplies BMI and ideal body weight calculators (MDCalc and CDC BMI) to support clinical measurement but does not list specific prior authorization requirements in this section.

    • MDCalc link for ideal and adjusted body weight (Devine formula) and CDC adult BMI calculator are provided.
    • No explicit prior authorization codes or requirements are specified in the appendix/background chunks.
    Prior Authorization

    Prior authorization (not specified here)

    This section of the background does not include specific prior authorization code requirements; see main policy sections for any plan-specific prior authorization procedures.

    • Clinical Policy Bulletin is a partial description of plan benefits and does not substitute for plan provisions that may include prior authorization rules.
    Note

    Medication adjunct requirement

    Weight reduction medications should be used as adjuncts to diet, exercise, and behavioral modification and reserved for patients who have not achieved adequate weight loss with lifestyle measures alone.

    • Consider pharmacotherapy only after documented failure of caloric restriction, increased physical activity, and behavioral modification.
    • Initial response (e.g., lack of ≥2 kg weight loss in first 4 weeks) predicts poor long‑term response and should inform continuation decisions.
    Denial Risk

    Concomitant therapy restriction

    Do not combine liraglutide (Saxenda) with other GLP‑1 receptor agonists (for example, Victoza); liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).

    • Saxenda and Victoza contain the same active ingredient at different doses; concurrent use is not indicated.
    • Boxed warning and contraindications for MTC and MEN2 must be reviewed and documented.
    Documentation Required

    Requirement for concurrent lifestyle program

    Plenity effectiveness in trials was measured with concurrent diet and exercise; payers may require documentation that patients are participating in and adhering to a structured lifestyle modification program while using Plenity.

    • GLOW trial prescribed reduced caloric intake and exercise for all subjects; documentation of lifestyle counseling/adherence may be requested.
    • Plenity is intended for use as an adjunct to diet and exercise, not as a standalone substitute for nutritional intake.
    Step Therapy

    No step therapy requirements described

    No step therapy requirements for SGLT2 inhibitors or other agents are described in these background chunks; the document does not define a step‑therapy sequence in this section.

    • Background material reports evidence reviews but does not establish payer step therapy rules here.
    • Refer to pharmacy PA policy for specific step therapy or formulary requirements.
    Note
    Documentation Required

    Required clinical tests and monitoring

    For VLCDs and medical evaluation of overweight/obese individuals, document ordered/performed baseline and monitoring tests including CBC, metabolic/chemistry profiles, lipid profile, thyroid tests, glucose tolerance testing (when indicated), ECG (adult), and scheduled serum chemistries and LFTs weekly during rapid weight loss then every 2 weeks up to 16 weeks.

    • Baseline evaluation: CBC, comprehensive history and physical, lipid profile, metabolic and chemistry profile, thyroid function tests, urinalysis, ECG (adult), GTT when indicated.
    • VLCD monitoring: EKG after 50 lbs lost; lipid profile at start and end; weekly serum chemistries and LFTs during rapid phase, then every 2 weeks up to 16 weeks.
    Documentation Required

    Required documentation for GLP-1 receptor agonist therapy

    When prescribing GLP‑1 receptor agonist therapy (liraglutide), document baseline BMI and weight, any weight‑related comorbidities, contraindications (personal/family history of MTC or MEN2), and weight change at approximately 16 weeks to justify continuation or discontinuation.

    • Record baseline BMI/weight and presence of weight‑related comorbidities to meet indication criteria (BMI ≥30 or ≥27 with comorbidity).
    • Capture and document percent weight change at ~16 weeks to determine whether liraglutide should be discontinued if <4% weight loss.
    Documentation Required

    Patient counseling and documentation

    Advise patients taking Plenity to take the product under the direction of a healthcare provider as part of a structured weight loss program and to discontinue and contact their HCP for severe adverse events, inability to swallow capsules, or if capsules are damaged.

    • Patients should stop Plenity and contact HCP for severe allergic reaction, severe abdominal pain, or severe diarrhea.
    • Do not use Plenity in pregnancy or with known allergies to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium oxide.
    Documentation Required

    Weight and BMI calculation resources

    Links to external calculators (MDCalc for ideal/adjusted body weight using the Devine formula and CDC adult BMI calculator) are provided to support consistent weight and BMI calculations; providers should use these resources when documenting BMI and weight.

    • MDCalc: Ideal Body Weight and Adjusted Body Weight (Devine formula).
    • CDC Adult BMI Calculator for computing BMI.
    Note

    Clinical policy bulletin note

    Clinical Policy Bulletins provide a partial, general description of plan benefits and do not constitute a contract; providers remain responsible for treatment decisions and must follow specific plan provisions which may affect coverage or authorization.

    • Verify member benefit plan details for exclusions or prior authorization requirements before delivering services.
    • CPB information may be updated; providers should confirm current plan provisions.
    Denial Risk

    Benefit exclusion may trigger denial

    Claims for weight reduction medications and physician supervision of weight reduction programs will be denied if the member's benefit plan specifically excludes services and supplies related to obesity, diet, or weight control—confirm benefits prior to ordering or billing.

    • Check benefit plan descriptions for exclusions; under excluded plans, claims will be denied regardless of medical necessity criteria.
    • Diagnostic tests required solely by non‑covered weight loss programs are not covered under most plans.
    Denial Risk

    Liraglutide treatment stopping rule

    Per FDA labeling for liraglutide (Saxenda), evaluate patients at 16 weeks and discontinue treatment if they have not lost at least 4% of baseline body weight, as continued treatment is unlikely to be effective.

    • Document weight at baseline and at 16 weeks to support continuation or discontinuation decisions.
    • Failure to meet the 4% threshold should prompt discontinuation per labeling.
    Denial Risk

    Contraindications and precautions for Plenity

    Plenity is contraindicated in pregnancy and in patients with a history of allergic reaction to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium oxide; use caution or avoid in patients with active GI conditions or anatomic anomalies that affect swallowing or GI transit.

    • Avoid Plenity in patients with esophageal anomalies, suspected strictures, prior GI surgery affecting transit, or inability to swallow capsules.
    • Instruct patients to discontinue and contact HCP for severe allergic reactions or severe GI symptoms.
    Note

    None stated in this section

    No additional provider actions are specified in these background and evidence summary chunks regarding authorization or denial triggers; refer to the main policy coverage criteria for concrete prior authorization rules.

    • Background sections summarize evidence and do not replace the policy's coverage/authorization criteria.
    • See policy coverage sections for any required forms, documentation, or authorization workflows.
    Prior Authorization

    No explicit authorization or denial trig

    These background chunks do not provide explicit authorization or denial triggers; providers should consult the main policy sections and member benefit documents for prior authorization requirements.

    • Policy history and additional information sections reiterate that CPBs are partial descriptions and plan provisions govern coverage.
    • Contact the payer for specific prior authorization processes when codes/services are planned.

    Background and Evidence Summaries

    Weight reduction medications and programs are adjuncts to calorie restriction, increased physical activity, and behavioral modification. Medication-induced weight loss is generally part of a comprehensive program and requires monitoring; for some agents (for example, liraglutide), regulatory labeling and clinical trials define specific eligibility criteria, monitoring intervals, and stopping rules to assess efficacy and safety.

    Definitions

    Very Low Calorie Diet (VLCD)
    DefinitionVery Low Calorie Diet (VLCD) = diet providing less than 799 kcal/day
    Covered monitoringMedically necessary monitoring during VLCD includes EKG after 50 lb weight loss; lipid profile at program start and end; weekly serum chemistries and LFTs during rapid weight loss then every 2 weeks up to 16 weeks
    Review for extensionVLCDs beyond 16 weeks require medical review to determine medical necessity of additional monitoring
    Plenity
    IndicationPlenity (Gelesis) is FDA-cleared as an adjunct to diet and exercise for adults with BMI 25–40 kg/m2 and is considered medically necessary when criteria are met
    Device descriptionOral superabsorbent hydrogel capsules (0.75 g per capsule; 3 capsules = 2.25 g per dose) taken with water before lunch and dinner to increase satiety; nonsystemic action in GI tract
    HCPCS codingNo specific HCPCS code identified in the policy; Plenity listed as device/HCPCS: Plenity (Gelesis, Inc.)
    Medication use criteria
    Adjunctive useWeight reduction medications should be used as an adjunct to caloric restriction, exercise, and behavioral modification
    Failure of behavioral therapyMedications are reserved for individuals who have not achieved adequate weight loss with lifestyle interventions; early response predicts long-term benefit
    Early response ruleLack of ≥2 kg weight loss in the first 4 weeks predicts low likelihood of long-term response
    Liraglutide (Saxenda)
    IndicationLiraglutide (Saxenda) is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one weight-related comorbidity
    Boxed warning/contraindicationBoxed warning for rodent thyroid C‑cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2
    Class restrictionShould not be used in combination with other GLP-1 receptor agonists (e.g., Victoza) due to same active ingredient
    Body composition measurement modalities
    Included modalitiesWhole‑body DEXA, bioelectrical impedance analysis (BIA)/BIVA, and indirect calorimetry
    Clinical utilityAvailable evidence does not establish that routine use of these body composition or metabolic measurement modalities improves clinical outcomes compared with BMI/anthropometrics
    Use caseThese modalities may be appropriate for research or selected clinical contexts where specific utility is documented, but are not supported for routine obesity management
    Plenity
    Dosage per labelingPlenity dosing: three capsules (2.25 g/dose) with water before lunch and before dinner; capsules disintegrate in stomach and release hydrogel particles
    Mechanism and clearanceHydrogel particles hydrate and occupy gastric volume to promote satiety; nonsystemic and eliminated in stool
    FDA pathwayCleared via the FDA De Novo pathway for adults with BMI 25–40 kg/m2 when used with diet and exercise
    Bioelectrical Impedance Analysis (BIA)/BIVA
    Method descriptionBioelectrical Impedance Analysis (BIA)/BIVA are noninvasive methods to estimate body composition and hydration
    Accuracy factorsAccuracy depends on prediction equations, device, and consistent testing conditions; estimates show substantial variability across populations and equations
    Recommended useBIA estimations may be useful when performed longitudinally and under standardized conditions, but validity and measurement error limit routine use in obesity management
    FTO genotyping (rs9939609)
    Genetic markerFTO rs9939609 variant is associated with variability in weight loss response to diet/lifestyle interventions
    Effect sizeMeta-analyses suggest homozygous A-allele (AA) carriers may have modestly greater weight loss (~0.44 kg greater vs TT in one analysis), but results are inconsistent
    Clinical applicationClinical applications require further investigation and are not established for routine management
    Ideal body weight (Devine formula) / Adjusted body weight
    Calculation methodIdeal and adjusted body weight can be computed using the Devine formula (external MDCalc link provided)
    Resource linkMDCalc Ideal Body Weight and Adjusted Body Weight calculator referenced in policy appendix
    UseProvides standardized method to compute ideal/adjusted weight for dosing and assessment
    BMI (adult)
    BMI calculationAdult BMI calculation resource referenced (CDC adult BMI calculator)
    Formula reminderBMI = weight (kg) / [height (m)]² (policy provides link to calculator)
    ContextBMI thresholds in policy (e.g., ≥30 kg/m2 for obesity) are used to determine eligibility for counseling visits and medication criteria